Canada manawa 2022-01-24, RhoVac, he pharmaceutical hui e pili ana i ka tumor immunology, hai mai la i kona palapala palapala palapala (No. 2710061) no kona cancer peptide vaccine RV001 e ae ia e ka Canadian Intellectual Property Office (CIPO).Ma mua, ua loaʻa i ka hui nā patent e pili ana iā RV001 ma United States, Europe a me Iapana.Hāʻawi kēia hāʻawi patent i ka pale ākea no RV001 ma nā mākeke koʻikoʻi a hoʻonui i nā pale patent o ka hui.
E like me ka palapala patent i hāʻawi mua ʻia, uhi kēia patent i ka lāʻau lapaʻau RV001 a me kāna mau ʻano like ʻole, a me kona hoʻohana ʻana i ka mālama ʻana / pale ʻana i ka RhoC-expressing metastatic cancer.Ma waena o lākou, ʻo RhoC kahi antigen pili i ka tumo (TAA) i hoʻohālikelike ʻia i nā ʻano cell tumor like ʻole.Ke hāʻawi ʻia, e pau ka patent ma 2028-12 a manaʻo ʻia e hoʻonui ʻia ma ka loaʻa ʻana o kahi palapala hōʻoia no ka pale ʻana i ke kākoʻo (CSP).
01 Onilcamotide
ʻO ka Onilcamotide ka lāʻau lapaʻau maʻi maʻi i loaʻa nā peptides immunogenic i loaʻa mai Ras homologous ʻohana C (RhoC), hiki ke emulsified i loko o ka immune adjuvant montanide ISA-51, me nā hana immunomodulatory a me nā hana antitumor.Hoʻoulu ʻia ka lawelawe subcutaneous o Onilcamotide i ka ʻōnaehana immune host e kau i kahi pane humoral a cytotoxic T lymphocyte (CTL) i nā pūnaewele koko e hōʻike ana i ka RhoC, a laila e hoʻoheheʻe ʻia nā pūnaʻi tumo.
2020-11, ua hāʻawi ʻia ʻo RV001 i ka inoa Fast Track e ka FDA.
02 Nā hoʻokolohua lapaʻau
I ka makahiki 2018, ua ʻae ʻia ka hoʻokolohua lapaʻau Phase I/IIa o Onilcamotide no ka mālama ʻana i ka maʻi maʻi prostate, a he 21 mau mea maʻi i kākau inoa ʻia.Ua hōʻike ʻia nā hopena ua palekana a ʻae maikaʻi ʻia ʻo Onilcamotide.Eia kekahi, ua hoʻomohala ka poʻe maʻi i nā pane kūlohelohe ikaika a lōʻihi ma hope o ka mālama ʻana.I ka makahiki 2021, he 19 o kēia mau kumuhana, ʻekolu mau makahiki ma hope o ka pau ʻana o ka mālama ʻana e RhoVac, ua hōʻike ʻia ʻaʻole i hoʻomohala kēia mau kumuhana i nā metastases a i ʻole i loaʻa i ka mālama hou aʻe a ʻaʻohe nui o ka prostate-specific antigen (PSA) holomua..ʻO kēia mau mea, ʻaʻohe PSA ʻike ʻia nā kumuhana 16, a ʻo nā kumuhana 3 i lohi i ka holomua PSA.ʻO PSA kahi protein i hana ʻia e ka prostate gland a hoʻohana ʻia e nānā i ka holomua o ka maʻi prostate i ʻike ʻia.
I ka makahiki 2019, ua hoʻomaka ʻia ka RV001 Phase IIb clinical BraVac (randomized, double-blind, placebo-controlled) e loiloi i kona pono i ka pale ʻana a i ʻole ka palena ʻana i ka hoʻomohala ʻana o ka maʻi maʻi prostate metastatic ma hope o ke ʻoki ʻana/radiation.ʻO kēia hoʻokolohua hoʻokolohua IIb he honua, multicenter study recruiting subjects in 6 European country (Denmark, Finland, Sweden, Belgium, Germany, and the United Kingdom) a me ʻAmelika Hui Pū ʻIa.Ua hoʻopau ka hoʻokolokolo i ka hoʻopaʻa ʻana i ka maʻi ma 2021-09, me ka huina o 175 mau kumuhana i kākau inoa ʻia, a e pau i ka 2022H1.Eia kekahi, hoʻolālā ʻo RhoVac e hana i nā haʻawina exploratory preclinical e kuhikuhi ana i ka hāʻawi ʻana i nā hōʻike hōʻike no ka hoʻonui ʻana o RV001 i nā hōʻailona.
Eia kekahi, ua hana pū ke komite kiaʻi palekana i kahi loiloi palekana interim o RV001 ma 2021-07, a ʻaʻohe mea i manaʻo ʻole ʻia i ʻike ʻia, i kūlike me ka hopena mua o ka hopena I/II.
Ka manawa hoʻouna: Feb-17-2022